Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration

Yangqing Sun; Qingqing Liu; Shangwei Zhong; Rui Wei; Jun-Li Luo

doi:10.3390/cancers16030597

Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration

Cancers (Basel). 2024 Jan 31;16(3):597. doi: 10.3390/cancers16030597.

Authors

Yangqing Sun¹, Qingqing Liu¹, Shangwei Zhong², Rui Wei¹, Jun-Li Luo^{1

2

3}

Affiliations

¹ Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
² The Cancer Research Institute and the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
³ National Health Commission Key Laboratory of Birth Defect Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China.

Abstract

FtsJ RNA 2'-O-methyltransferase 1 (FTSJ1) is a member of the methyltransferase superfamily and is involved in the processing and modification of ribosomal RNA. We herein demonstrate that FTSJ1 favors TNBC progression. The knockdown of FTSJ1 inhibits TNBC cell proliferation and development, induces apoptosis of cancer cells, and increases the sensitivity of TNBC cells to T-cell-mediated cytotoxicity. Furthermore, the high expression of FTSJ1 in TNBC attenuates CD8+T cell infiltration in the tumor microenvironment (TME) correlated with poorer prognosis for clinical TNBC patients. In this study, we establish that FTSJ1 acts as a tumor promotor, is involved in cancer immune evasion, and may serve as a potential immunotherapy target in TNBC.

Keywords: CD8+T cell infiltration; FTSJ1; triple-negative breast cancer; tumor promotor.

Abstract

Grants and funding